Biotechnology

Celldex Therap

Celldex Therap released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 15 K (forecast USD 861 K), actual EPS USD -1.182 (forecast USD -1.163)

Celldex Therap released FY2025 annual earnings on February 25 (EST), actual revenue USD 1.545 M (forecast USD 2.746 M), actual EPS USD -3.8956 (forecast USD -3.6735)

Celldex Therap released FY2025 Q4 earnings on February 25 (EST), actual revenue USD 121K (forecast USD 1.464M), actual EPS USD -1.2273 (forecast USD -1.0168)

Cedars Medical to Present Barzolvolimab Phase 2 Data at the AAAAI Annual Meeting

Celldex Therap released FY2025 9 Months earnings on November 10, 2025 (EST), actual revenue USD 1.425 M, actual EPS USD -2.6729

Celldex Therap released FY2025 Q3 earnings on November 10 (EST), actual revenue USD 0 (forecast USD 1.084 M), actual EPS USD -1.0093 (forecast USD -0.9063)

Celldex Therap released FY2025 Semi-Annual earnings on August 7 (EST), actual revenue USD 1.424 M (forecast USD 2.75 M), actual EPS USD -1.6628 (forecast USD -1.48)

Celldex Therap released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 730K (forecast USD 1.132M), actual EPS USD -0.8525 (forecast USD -0.8663)

Cedars Medical Presents Phase II Study Data on Chronic Spontaneous Urticaria Drug

Sedaris Medical to Present Bazolovi Monoclonal Antibody Phase II Data at EAACI

Northern Trust Increased Stake in Cidara Therapeutics

Morgan Stanley Downgrades Cedars Medical Target Price to $43

Celldex Therap released FY2025 Q1 earnings on May 8 (EST), actual revenue USD 695K (forecast USD 1.121M), actual EPS USD -0.8103 (forecast USD -0.7714)

Cedars Medical Reports Q1 2025 Revenue Growth and Expanded Net Loss

Morgan Stanley Upgrades Celldex Therapeutics to Overweight with Target Price of $46

Sedes Medical Presents Positive Preclinical Data for CDX-622 at the 2025 AAAAI Annual Meeting

Celldex Therap released FY2024 Q4 earnings on February 27 (EST), actual revenue $1.175M (forecast $1.252M), actual EPS -$0.7097 (forecast -$0.7279)

Celldex Therap released FY2024 Annual Earnings on February 27 (EST), actual revenue $7.02M (forecast $6.863M), actual EPS -$2.4514 (forecast -$2.4725)

Sedes Medical Reports Quarterly Financial Data

Celldex Therapeutics released FY2024 Q3 earnings on November 6, 2024 (EST), actual revenue $3.191M (forecast $1.074M), actual EPS -0.6353 (forecast -0.6766)

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

CLDX

GLUC

CODX

ANVS

In Tuesday's after-market session, Co-Diagnostics shares surged 20.8% to $2.38, while Celldex Therapeutics rose 16.05% to $34.99. Other gainers included INVO Fertility (+13.28%) and Evaxion (+7.78%). Conversely, Annovis Bio fell 18.1% to $1.59, with GlucoTrack down 17.56%. Wellgistics Health and NexGel also saw declines of 10.72% and 10.41%, respectively. Most companies reported Q1 earnings recently.

benzinga_article

Glucose Health, Inc.

Co-Diagnostics

Annovis Bio

iShares US Pharma

Health Care Select Sector SPDR

SPDR S&P Health Equip

iShares Global Healthcare

INVO Fertility

Evaxion A/S

NeuroOne Medical Tech

Biorestorative Therapies

GlucoTrack

Wellgistics Health

Nexgel

AIM ImmunoTech

Icecure Medical

NEXGEL INC C/WTS 27/12/2026 (TO PUR COM)

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

12 Health Care Stocks Moving In Tuesday's After-Market Session

Barclays has raised its target price for Celldex Therapeutics (NASDAQ:CLDX) from $45.00 to $48.00, maintaining an "overweight" rating. This new target suggests a potential upside of 45.09% from the stock's previous close. Other analysts have also adjusted their ratings, with Goldman Sachs increasing their target to $34.00 and Stifel Nicolaus raising it to $68.00. Currently, Celldex has an average rating of "Moderate Buy" and a consensus price target of $46.64. The stock traded at $33.08, with a market cap of $2.60 billion and a P/E ratio of -8.49.

Market Beat

Barclays

Goldman Sachs

Stifel Financial

GS Hldg R

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Barclays Forecasts Strong Price Appreciation for Celldex Therapeutics (NASDAQ:CLDX) Stock

AMLX

SRTS

In Friday's pre-market session, Traws Pharma (NASDAQ:TRAW) shares surged 37% to $2.33, while Amylyx Pharmaceuticals (NASDAQ:AMLX) rose 18.42% to $18.0. Other gainers included Celldex Therapeutics (NASDAQ:CLDX) up 12.54% to $37.5, and InMed Pharmaceuticals (NASDAQ:INM) up 12% to $0.78. Conversely, Sensus Healthcare (NASDAQ:SRTS) fell 25.1% to $3.08, Absci (NASDAQ:ABSI) dropped 19.66% to $4.62, and Amphastar Pharma (NASDAQ:AMPH) decreased 15.65% to $20.27. Most companies reported Q1 earnings yesterday.

InMed Pharmaceuticals

Amylyx Pharmaceuticals

Sensus Healthcare

Amphastar Pharma

Traws Pharma

Absci

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Progyny

Artiva Biotherapeutics

Capricor Therap

Organogenesis

Artivion

12 Health Care Stocks Moving In Friday's Pre-Market Session

Earnings Watch

Celldex Therap | 8-K: FY2026 Q1 Revenue: USD 15 K

Celldex Therap | 10-Q: FY2026 Q1 Revenue: USD 15 K

FTXL

SOXX

SOXQ

Seagate Technology Holdings (STX) has experienced significant share price gains, with a 36.15% return over the past month and 62.66% over three months. Currently trading at $559.90, it is considered 15.9% overvalued compared to a fair value of $483.07. Despite this, a discounted cash flow model suggests a future value of $618.34 per share, indicating potential undervaluation. Investors are advised to weigh the risks and rewards, including trade policy shifts and competition in storage technologies, while exploring other investment opportunities in the data infrastructure sector.

Simplywall

Seagate Tech

SPDR S&P Semicon

First Trust Nasdaq Food & Semicon

iShares Semiconductor ETF

VanEck Semiconductor ETF

Invesco PHLX Semiconductor ETF

Assessing Seagate Technology Holdings (STX) Valuation After Strong Recent Share Price Gains

Celldex Therapeutics (NASDAQ:CLDX) shares gapped up after Barclays upgraded the stock from underweight to overweight, raising the price target from $24 to $45. The stock opened at $35.79, up from a previous close of $34.55. Other analysts have also issued positive ratings, with a consensus rating of "Moderate Buy" and an average target price of $46.36. The company reported a quarterly EPS of ($1.22), missing estimates, and has a market cap of $2.31 billion. Celldex focuses on developing targeted immunotherapies for cancer and serious diseases.

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up  Following Analyst Upgrade

Celldex (CLDX) stock received a double upgrade from Barclays analyst Etzer Darout, raising its rating to Overweight and price target to $45 from $25, indicating a potential 30.25% upside. This upgrade follows positive results from its Phase 3 clinical trial for barzolvolimab, which showed strong demand. Despite a premarket rally, the stock is slightly down today but has risen 27.21% year-to-date and 82.42% over the past year, with trading volume below average.

- Celldex (CLDX) shares fluctuated following a double upgrade to "outperform" by Barclays analyst Etzer Darout, who increased the price target from $25 to $45, indicating a potential 30.25% increase.  
- The analyst highlighted strong demand for the company's drug barzolvolimab, supported by positive phase three clinical trial results, which are expected to be released in Q4 2025.  
- Despite a slight decline in early trading, CLDX has risen 27.21% year-to-date and 82.42% over the past 12 months, with trading activity at about 95,000 shares, below the three-month average of 1.17 million shares.

Tip Ranks

A Top Wall Street Analyst 'Can't Ignore' Celldex Stock (CLDX)

Celldex Therap(CLDX.US)